Lixisenatide requires daily injections, while newer GLP-1-targeting drugs like Ozempic and Wegovy, as well as Eli Lilly’s tirzepatide-based Mounjaro and Zepbound, only need to be given once a ...

In what has been hailed a 'significant step forward' for treatment of the disease, a trial found lixisenatide reduced ... Half were given daily injections of the licensed diabetes drug and the ...